Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 5/20 | 0.39 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | TPH1 | P17752 | 1/20 | 0.35 |
| ▸ | TPH2 | Q8IWU9 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.32 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.32 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6704154 | 0.78 | MMP13 (0.39) | MMP13SLC22A8SLC6A3PTGER4LTA4H | |
| SCHEMBL6700586 | 0.77 | PTGER4 (0.46) | MMP13PTGER4ALDH1A1MEN1KMT2A | |
| SCHEMBL6700337 | 0.72 | MMP13 (0.41) | MMP13SLC22A8PTGER4ALDH1A1MEN1 | |
| SCHEMBL6702239 | 0.72 | MMP13 (0.41) | MMP13SLC22A8SLC6A3PTGER4ALDH1A1 | |
| SCHEMBL6702349 | 0.70 | CLPP (0.35) | SLC6A3ALDH1A1TP53KDM4E | |
| SCHEMBL6488588 | 0.68 | L3MBTL1 (0.35) | MMP13LTA4HALDH1A1AGTR1AGTR2 | |
| SCHEMBL6699557 | 0.67 | TP53 (0.47) | PTGER4ALDH1A1MEN1KMT2ATP53 | |
| SCHEMBL6818741 | 0.67 | MMP13 (0.44) | MMP13PTGER4TAS2R14CXCR3 | |
| SCHEMBL6699803 | 0.65 | PTGER4 (0.48) | MMP13PTGER4ALDH1A1 | |
| SCHEMBL6699527 | 0.65 | ENPP2 (0.36) | MMP13SLC22A8PTGER4AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | MMP13 13/4885SLC22A8 2959/4885SLC6A3 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.